# üéØ Primary Endpoint - –ê–Ω–∞–ª–∏–∑ –∏—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏—è

## ‚ùì –¢–µ–∫—É—â–∞—è —Å–∏—Ç—É–∞—Ü–∏—è

### –ì–¥–µ —Å–æ—Ö—Ä–∞–Ω—è–µ—Ç—Å—è:
```typescript
// app/dashboard/projects/new/page.tsx
const designJson = {
  design_type: formData.design_type,
  blinding: formData.blinding,
  arms: parseInt(formData.arms),
  duration_weeks: parseInt(formData.duration_weeks),
  primary_endpoint: formData.primary_endpoint, // ‚Üê –°–æ—Ö—Ä–∞–Ω—è–µ—Ç—Å—è –∑–¥–µ—Å—å
}

// –°–æ—Ö—Ä–∞–Ω—è–µ—Ç—Å—è –≤ projects.design_json
```

### –ì–¥–µ –æ—Ç–æ–±—Ä–∞–∂–∞–µ—Ç—Å—è:
```tsx
// app/dashboard/projects/[id]/page.tsx
<span className="text-gray-600">Primary Endpoint:</span>
<span className="font-medium">{designJson?.primary_endpoint || 'N/A'}</span>
```

### –ì–¥–µ –ù–ï –∏—Å–ø–æ–ª—å–∑—É–µ—Ç—Å—è (–ø—Ä–æ–±–ª–µ–º–∞!):
‚ùå **–ù–ï –ø–µ—Ä–µ–¥–∞–µ—Ç—Å—è –≤ AI –ø—Ä–æ–º–ø—Ç—ã –¥–ª—è –≥–µ–Ω–µ—Ä–∞—Ü–∏–∏ –¥–æ–∫—É–º–µ–Ω—Ç–æ–≤**
‚ùå **–ù–ï –∏—Å–ø–æ–ª—å–∑—É–µ—Ç—Å—è –≤ Protocol prompt**
‚ùå **–ù–ï –∏—Å–ø–æ–ª—å–∑—É–µ—Ç—Å—è –≤ Synopsis prompt**
‚ùå **–ù–ï –∏—Å–ø–æ–ª—å–∑—É–µ—Ç—Å—è –≤ IB prompt**

---

## üîç –ö–∞–∫ –î–û–õ–ñ–ù–û —Ä–∞–±–æ—Ç–∞—Ç—å

### Primary Endpoint - —ç—Ç–æ –∫–ª—é—á–µ–≤–∞—è –∏–Ω—Ñ–æ—Ä–º–∞—Ü–∏—è –¥–ª—è:

#### 1. **Protocol (Section 6: Objectives and Endpoints)**
```markdown
### 6. STUDY OBJECTIVES AND ENDPOINTS

#### 6.1 Primary Objective
To evaluate the effect of AST-101 on **HbA1c reduction** 
in patients with Type 2 Diabetes

#### 6.3 Primary Efficacy Endpoint
**Change from baseline in HbA1c at Week 24**
- Assessment method: Central laboratory
- Timing: Baseline, Week 12, Week 24
- Analysis: ANCOVA with baseline as covariate
```

#### 2. **Synopsis (Section 3: Study Endpoints)**
```markdown
### 3. STUDY ENDPOINTS

#### Primary Endpoint
**Change from baseline in HbA1c at Week 24**

Target: -0.8% reduction vs placebo (p<0.05)
```

#### 3. **IB (Section 7.2: Pharmacodynamics)**
```markdown
#### 7.2 Pharmacodynamics

Key endpoints for AST-101 evaluation:
- **Primary: HbA1c reduction at Week 24**
- Secondary: Fasting glucose, body weight
```

#### 4. **Statistical Analysis Plan**
```markdown
### Sample Size Calculation
Based on primary endpoint (HbA1c reduction):
- Expected difference: -0.8%
- Standard deviation: 1.2%
- Power: 90%
- Alpha: 0.05
- Required N: 180 subjects (90 per arm)
```

---

## ‚ùå –¢–µ–∫—É—â–∞—è –ø—Ä–æ–±–ª–µ–º–∞

### –ß—Ç–æ –ø—Ä–æ–∏—Å—Ö–æ–¥–∏—Ç —Å–µ–π—á–∞—Å:

**User –≤–≤–æ–¥–∏—Ç:**
```
Primary Endpoint: Change in HbA1c from baseline at Week 24
```

**AI –≥–µ–Ω–µ—Ä–∏—Ä—É–µ—Ç Protocol:**
```markdown
### 6.3 Primary Efficacy Endpoint
Change from baseline in [primary measure] ‚Üê Generic placeholder!
```

**–ü—Ä–æ–±–ª–µ–º–∞:**
- AI –Ω–µ –∑–Ω–∞–µ—Ç —á—Ç–æ primary endpoint = "HbA1c at Week 24"
- –ò—Å–ø–æ–ª—å–∑—É–µ—Ç generic placeholders
- –î–æ–∫—É–º–µ–Ω—Ç –≤—ã–≥–ª—è–¥–∏—Ç –Ω–µ–ø–æ–ª–Ω—ã–º
- Medical writer –¥–æ–ª–∂–µ–Ω –≤—Ä—É—á–Ω—É—é –∑–∞–ø–æ–ª–Ω—è—Ç—å

---

## ‚úÖ –†–µ—à–µ–Ω–∏–µ

### 1. –ü–µ—Ä–µ–¥–∞–≤–∞—Ç—å design_json –≤ –ø—Ä–æ–º–ø—Ç—ã

**–¢–µ–∫—É—â–∏–π –∫–æ–¥ (generate-document/index.ts):**
```typescript
const context = {
  project: {
    title: project.title,
    phase: project.phase,
    indication: project.indication,
    countries: project.countries,
    design: project.design_json, // ‚Üê –ü–µ—Ä–µ–¥–∞–µ—Ç—Å—è, –Ω–æ –Ω–µ –∏—Å–ø–æ–ª—å–∑—É–µ—Ç—Å—è!
  },
  // ...
}
```

**–ü—Ä–æ–º–ø—Ç—ã –¥–æ–ª–∂–Ω—ã –∏—Å–ø–æ–ª—å–∑–æ–≤–∞—Ç—å:**
```typescript
// lib/prompts/protocol-prompt.ts
export function generateProtocolPrompt(context: any) {
  const { project, entities } = context
  const design = project.design || {}
  
  const primaryEndpoint = design.primary_endpoint || 
                          entities.endpoint?.[0] || 
                          'Change from baseline in [primary measure]'
  
  return `
### 6.3 Primary Efficacy Endpoint
${primaryEndpoint}
  `
}
```

---

## üîß –ò—Å–ø—Ä–∞–≤–ª–µ–Ω–∏—è

### Fix 1: Protocol Prompt

**File**: `lib/prompts/protocol-prompt.ts`

**–î–æ:**
```typescript
#### 6.1 Primary Objective
${endpoints.length > 0 ? `To evaluate ${endpoints[0]}` : `To evaluate efficacy`}

#### 11.1 Primary Efficacy Endpoint
${endpoints[0] || 'Change from baseline in [primary measure]'}
```

**–ü–æ—Å–ª–µ:**
```typescript
// Extract primary endpoint from design_json or entities
const primaryEndpoint = project.design?.primary_endpoint || 
                        endpoints[0] || 
                        'Change from baseline in [primary measure]'

#### 6.1 Primary Objective
To evaluate ${primaryEndpoint} in patients with ${indication}

#### 11.1 Primary Efficacy Endpoint
${primaryEndpoint}
- Assessment method: [specify]
- Timing: Baseline, [timepoints]
- Analysis: [statistical method]
```

---

### Fix 2: Synopsis Prompt

**File**: `lib/prompts/synopsis-prompt.ts`

**–î–æ:**
```typescript
#### Primary Endpoint
${endpoints[0] || 'Change from baseline in [primary measure] at Week [X]'}
```

**–ü–æ—Å–ª–µ:**
```typescript
const primaryEndpoint = project.design?.primary_endpoint || 
                        endpoints[0] || 
                        'Change from baseline in [primary measure]'

#### Primary Endpoint
${primaryEndpoint}

**Target**: [specify target difference vs comparator]
**Analysis**: [statistical method]
```

---

### Fix 3: IB Prompt

**File**: `lib/prompts/ib-prompt.ts`

**–î–æ:**
```typescript
- Biomarkers and surrogate endpoints
${endpoints.length > 0 ? `- Key endpoints: ${endpoints.join(', ')}` : ''}
```

**–ü–æ—Å–ª–µ:**
```typescript
const primaryEndpoint = project.design?.primary_endpoint
const allEndpoints = primaryEndpoint 
  ? [primaryEndpoint, ...endpoints]
  : endpoints

- Biomarkers and surrogate endpoints
${allEndpoints.length > 0 ? `- Key endpoints: ${allEndpoints.join(', ')}` : ''}
```

---

## üìä –°—Ä–∞–≤–Ω–µ–Ω–∏–µ: –î–æ vs –ü–æ—Å–ª–µ

### –î–æ (–±–µ–∑ primary_endpoint):

**Protocol Section 6:**
```markdown
### 6. STUDY OBJECTIVES AND ENDPOINTS

#### 6.1 Primary Objective
To evaluate the efficacy and safety of AST-101

#### 6.3 Primary Efficacy Endpoint
Change from baseline in [primary measure]
- Assessment method
- Timing of assessments
```
‚ùå Generic, –Ω–µ–ø–æ–ª–Ω—ã–π

---

### –ü–æ—Å–ª–µ (—Å primary_endpoint):

**Protocol Section 6:**
```markdown
### 6. STUDY OBJECTIVES AND ENDPOINTS

#### 6.1 Primary Objective
To evaluate the effect of AST-101 on **change in HbA1c 
from baseline at Week 24** in patients with Type 2 Diabetes

#### 6.3 Primary Efficacy Endpoint
**Change from baseline in HbA1c at Week 24**
- Assessment method: Central laboratory (HPLC)
- Timing: Baseline, Week 12, Week 24
- Analysis: ANCOVA with baseline HbA1c as covariate
- Target: -0.8% reduction vs placebo (p<0.05)
```
‚úÖ Specific, complete, professional!

---

## üéØ –î–æ–ø–æ–ª–Ω–∏—Ç–µ–ª—å–Ω—ã–µ —É–ª—É—á—à–µ–Ω–∏—è

### 1. Validation –ø—Ä–∏ —Å–æ–∑–¥–∞–Ω–∏–∏ –ø—Ä–æ–µ–∫—Ç–∞

```tsx
// Suggest primary endpoint based on indication
const primaryEndpointSuggestions = {
  'diabetes': 'Change in HbA1c from baseline at Week 24',
  'hypertension': 'Change in systolic blood pressure at Week 12',
  'depression': 'Change in MADRS score at Week 8',
  'pain': 'Change in pain intensity (VAS) at Week 4',
}

// Show suggestion
{indication && (
  <p className="text-xs text-blue-600">
    üí° Suggested: {primaryEndpointSuggestions[indication.toLowerCase()]}
  </p>
)}
```

### 2. Secondary Endpoints

```tsx
// Add secondary endpoints field
<label>Secondary Endpoints (optional)</label>
<textarea
  value={formData.secondary_endpoints}
  placeholder="e.g., Fasting glucose, Body weight, Quality of life"
/>
```

### 3. Endpoint Details

```tsx
// Add endpoint timing
<label>Primary Endpoint Timepoint</label>
<Input
  value={formData.endpoint_timepoint}
  placeholder="e.g., Week 24, Month 6, Day 28"
/>
```

---

## üí° –ü–æ—á–µ–º—É —ç—Ç–æ –≤–∞–∂–Ω–æ?

### 1. **Regulatory Compliance** üìã
FDA/EMA —Ç—Ä–µ–±—É—é—Ç **—á–µ—Ç–∫–æ–µ –æ–ø—Ä–µ–¥–µ–ª–µ–Ω–∏–µ** primary endpoint:
- –ß—Ç–æ –∏–∑–º–µ—Ä—è–µ—Ç—Å—è
- –ö–æ–≥–¥–∞ –∏–∑–º–µ—Ä—è–µ—Ç—Å—è
- –ö–∞–∫ –∞–Ω–∞–ª–∏–∑–∏—Ä—É–µ—Ç—Å—è

### 2. **Statistical Planning** üìä
Sample size calculation **–∑–∞–≤–∏—Å–∏—Ç –æ—Ç** primary endpoint:
- Expected effect size
- Standard deviation
- Clinical significance

### 3. **Study Design** üî¨
Primary endpoint –æ–ø—Ä–µ–¥–µ–ª—è–µ—Ç:
- Duration of study
- Visit schedule
- Assessment methods
- Data collection

### 4. **Document Quality** ‚úÖ
–î–æ–∫—É–º–µ–Ω—Ç—ã —Å **specific endpoints** –≤—ã–≥–ª—è–¥—è—Ç:
- –ë–æ–ª–µ–µ –ø—Ä–æ—Ñ–µ—Å—Å–∏–æ–Ω–∞–ª—å–Ω–æ
- –ì–æ—Ç–æ–≤—ã –∫ submission
- –ú–µ–Ω—å—à–µ —Ç—Ä–µ–±—É—é—Ç —Ä–µ–¥–∞–∫—Ç–∏—Ä–æ–≤–∞–Ω–∏—è

---

## üöÄ Action Items

### Priority 1: Fix Prompts ‚ö°
1. ‚úÖ Update `protocol-prompt.ts` to use `design.primary_endpoint`
2. ‚úÖ Update `synopsis-prompt.ts` to use `design.primary_endpoint`
3. ‚úÖ Update `ib-prompt.ts` to include `design.primary_endpoint`

### Priority 2: Enhance UI üé®
1. Add endpoint suggestions based on indication
2. Add secondary endpoints field
3. Add endpoint timepoint field

### Priority 3: Validation ‚úÖ
1. Validate endpoint format
2. Suggest standard endpoints
3. Check endpoint matches indication

---

## üìù Summary

### –¢–µ–∫—É—â–∞—è —Å–∏—Ç—É–∞—Ü–∏—è:
‚ùå `primary_endpoint` —Å–æ—Ö—Ä–∞–Ω—è–µ—Ç—Å—è –Ω–æ **–ù–ï –∏—Å–ø–æ–ª—å–∑—É–µ—Ç—Å—è** –≤ AI –ø—Ä–æ–º–ø—Ç–∞—Ö
‚ùå –î–æ–∫—É–º–µ–Ω—Ç—ã —Å–æ–¥–µ—Ä–∂–∞—Ç generic placeholders
‚ùå Medical writer –¥–æ–ª–∂–µ–Ω –≤—Ä—É—á–Ω—É—é –∑–∞–ø–æ–ª–Ω—è—Ç—å

### –ü–æ—Å–ª–µ –∏—Å–ø—Ä–∞–≤–ª–µ–Ω–∏—è:
‚úÖ `primary_endpoint` –ø–µ—Ä–µ–¥–∞–µ—Ç—Å—è –≤ AI –ø—Ä–æ–º–ø—Ç—ã
‚úÖ –î–æ–∫—É–º–µ–Ω—Ç—ã —Å–æ–¥–µ—Ä–∂–∞—Ç **specific, detailed** endpoints
‚úÖ –ì–æ—Ç–æ–≤—ã –∫ regulatory submission
‚úÖ –ú–µ–Ω—å—à–µ manual editing

### Value:
- ‚è±Ô∏è –≠–∫–æ–Ω–æ–º–∏—è 1-2 —á–∞—Å–∞ –Ω–∞ –¥–æ–∫—É–º–µ–Ω—Ç (manual endpoint filling)
- üìä –õ—É—á—à–µ–µ –∫–∞—á–µ—Å—Ç–≤–æ –¥–æ–∫—É–º–µ–Ω—Ç–æ–≤
- ‚úÖ Regulatory compliance
- üíº –ü—Ä–æ—Ñ–µ—Å—Å–∏–æ–Ω–∞–ª—å–Ω—ã–π –≤–∏–¥

---

**Primary Endpoint = –ö–ª—é—á–µ–≤–∞—è –∏–Ω—Ñ–æ—Ä–º–∞—Ü–∏—è –¥–ª—è –≤—Å–µ—Ö –¥–æ–∫—É–º–µ–Ω—Ç–æ–≤!** üéØ

**Next**: Implement fixes –≤ –ø—Ä–æ–º–ø—Ç–∞—Ö! üöÄ
